Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 5Active not recruiting 4Unknown 3Recruiting 2Withdrawn 1Terminated 1

Sponsor Class

NIH 5OTHER 4NETWORK 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3CNS 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Glioblastoma 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × ipatasertib × Clear all
NCT05498896 2026-05-08

BARBICAN

Queen Mary University of London

Phase 2 Active not recruiting
146 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04920708 2026-04-14

FAIM

Royal Marsden NHS Foundation Trust

Phase 2 Active not recruiting
57 enrolled
Breast

Breast Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Massachusetts General Hospital

Phase 1 Active not recruiting
77 enrolled
Breast

Breast Neoplasms

NCT03673787 2025-05-14

IceCAP

Institute of Cancer Research, United Kingdom

Phase 1/2 Active not recruiting
87 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡